Compile Data Set for Download or QSAR
Report error Found 66 Enz. Inhib. hit(s) with all data for entry = 11826
TargetProtein cereblon(Human)
Monte Rosa Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 651638BDBM651638(US20240051936, Compound 44)
Affinity DataIC50: 600nMAssay Description:Compound activity was monitored in a fluorescence polarization (FP) homogeneous assay using 1-[5-({2-[2-(2-{[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/23/2024
Entry Details
US Patent

TargetProtein cereblon(Human)
Monte Rosa Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 651634BDBM651634(US20240051936, Compound 40)
Affinity DataIC50: 600nMAssay Description:Compound activity was monitored in a fluorescence polarization (FP) homogeneous assay using 1-[5-({2-[2-(2-{[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/23/2024
Entry Details
US Patent

TargetProtein cereblon(Human)
Monte Rosa Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 651605BDBM651605(US20240051936, Compound 11)
Affinity DataIC50: 600nMAssay Description:Compound activity was monitored in a fluorescence polarization (FP) homogeneous assay using 1-[5-({2-[2-(2-{[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/23/2024
Entry Details
US Patent

TargetProtein cereblon(Human)
Monte Rosa Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 651646BDBM651646(US20240051936, Compound 52)
Affinity DataIC50: 600nMAssay Description:Compound activity was monitored in a fluorescence polarization (FP) homogeneous assay using 1-[5-({2-[2-(2-{[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/23/2024
Entry Details
US Patent

TargetProtein cereblon(Human)
Monte Rosa Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 651647BDBM651647(US20240051936, Compound 53)
Affinity DataIC50: 600nMAssay Description:Compound activity was monitored in a fluorescence polarization (FP) homogeneous assay using 1-[5-({2-[2-(2-{[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/23/2024
Entry Details
US Patent

TargetProtein cereblon(Human)
Monte Rosa Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 651648BDBM651648(US20240051936, Compound 54)
Affinity DataIC50: 600nMAssay Description:Compound activity was monitored in a fluorescence polarization (FP) homogeneous assay using 1-[5-({2-[2-(2-{[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/23/2024
Entry Details
US Patent

TargetProtein cereblon(Human)
Monte Rosa Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 651611BDBM651611(US20240051936, Compound 17)
Affinity DataIC50: 600nMAssay Description:Compound activity was monitored in a fluorescence polarization (FP) homogeneous assay using 1-[5-({2-[2-(2-{[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/23/2024
Entry Details
US Patent

TargetProtein cereblon(Human)
Monte Rosa Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 651613BDBM651613(US20240051936, Compound 19)
Affinity DataIC50: 600nMAssay Description:Compound activity was monitored in a fluorescence polarization (FP) homogeneous assay using 1-[5-({2-[2-(2-{[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/23/2024
Entry Details
US Patent

TargetProtein cereblon(Human)
Monte Rosa Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 651654BDBM651654(US20240051936, Compound 60)
Affinity DataIC50: 600nMAssay Description:Compound activity was monitored in a fluorescence polarization (FP) homogeneous assay using 1-[5-({2-[2-(2-{[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/23/2024
Entry Details
US Patent

TargetProtein cereblon(Human)
Monte Rosa Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 651656BDBM651656(US20240051936, Compound 62)
Affinity DataIC50: 600nMAssay Description:Compound activity was monitored in a fluorescence polarization (FP) homogeneous assay using 1-[5-({2-[2-(2-{[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/23/2024
Entry Details
US Patent

TargetProtein cereblon(Human)
Monte Rosa Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 651650BDBM651650(US20240051936, Compound 56)
Affinity DataIC50: 600nMAssay Description:Compound activity was monitored in a fluorescence polarization (FP) homogeneous assay using 1-[5-({2-[2-(2-{[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/23/2024
Entry Details
US Patent

TargetProtein cereblon(Human)
Monte Rosa Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 651651BDBM651651(US20240051936, Compound 57)
Affinity DataIC50: 600nMAssay Description:Compound activity was monitored in a fluorescence polarization (FP) homogeneous assay using 1-[5-({2-[2-(2-{[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/23/2024
Entry Details
US Patent

TargetProtein cereblon(Human)
Monte Rosa Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 651652BDBM651652(US20240051936, Compound 58)
Affinity DataIC50: 600nMAssay Description:Compound activity was monitored in a fluorescence polarization (FP) homogeneous assay using 1-[5-({2-[2-(2-{[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/23/2024
Entry Details
US Patent

TargetProtein cereblon(Human)
Monte Rosa Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 651653BDBM651653(US20240051936, Compound 59)
Affinity DataIC50: 600nMAssay Description:Compound activity was monitored in a fluorescence polarization (FP) homogeneous assay using 1-[5-({2-[2-(2-{[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/23/2024
Entry Details
US Patent

TargetProtein cereblon(Human)
Monte Rosa Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 651631BDBM651631(US20240051936, Compound 37)
Affinity DataIC50: 600nMAssay Description:Compound activity was monitored in a fluorescence polarization (FP) homogeneous assay using 1-[5-({2-[2-(2-{[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/23/2024
Entry Details
US Patent

TargetProtein cereblon(Human)
Monte Rosa Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 651632BDBM651632(US20240051936, Compound 38)
Affinity DataIC50: 600nMAssay Description:Compound activity was monitored in a fluorescence polarization (FP) homogeneous assay using 1-[5-({2-[2-(2-{[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/23/2024
Entry Details
US Patent

TargetProtein cereblon(Human)
Monte Rosa Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 651660BDBM651660(US20240051936, Compound 73)
Affinity DataIC50: 600nMAssay Description:Compound activity was monitored in a fluorescence polarization (FP) homogeneous assay using 1-[5-({2-[2-(2-{[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/23/2024
Entry Details
US Patent

TargetProtein cereblon(Human)
Monte Rosa Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 651639BDBM651639(US20240051936, Compound 45)
Affinity DataIC50: 900nMAssay Description:Compound activity was monitored in a fluorescence polarization (FP) homogeneous assay using 1-[5-({2-[2-(2-{[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/23/2024
Entry Details
US Patent

TargetProtein cereblon(Human)
Monte Rosa Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 651640BDBM651640(US20240051936, Compound 46)
Affinity DataIC50: 900nMAssay Description:Compound activity was monitored in a fluorescence polarization (FP) homogeneous assay using 1-[5-({2-[2-(2-{[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/23/2024
Entry Details
US Patent

TargetProtein cereblon(Human)
Monte Rosa Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 651641BDBM651641(US20240051936, Compound 47)
Affinity DataIC50: 900nMAssay Description:Compound activity was monitored in a fluorescence polarization (FP) homogeneous assay using 1-[5-({2-[2-(2-{[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/23/2024
Entry Details
US Patent

TargetProtein cereblon(Human)
Monte Rosa Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 651636BDBM651636(US20240051936, Compound 42)
Affinity DataIC50: 900nMAssay Description:Compound activity was monitored in a fluorescence polarization (FP) homogeneous assay using 1-[5-({2-[2-(2-{[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/23/2024
Entry Details
US Patent

TargetProtein cereblon(Human)
Monte Rosa Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 651637BDBM651637(US20240051936, Compound 43)
Affinity DataIC50: 900nMAssay Description:Compound activity was monitored in a fluorescence polarization (FP) homogeneous assay using 1-[5-({2-[2-(2-{[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/23/2024
Entry Details
US Patent

TargetProtein cereblon(Human)
Monte Rosa Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 651614BDBM651614(US20240051936, Compound 20)
Affinity DataIC50: 900nMAssay Description:Compound activity was monitored in a fluorescence polarization (FP) homogeneous assay using 1-[5-({2-[2-(2-{[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/23/2024
Entry Details
US Patent

TargetProtein cereblon(Human)
Monte Rosa Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 651617BDBM651617(US20240051936, Compound 23)
Affinity DataIC50: 900nMAssay Description:Compound activity was monitored in a fluorescence polarization (FP) homogeneous assay using 1-[5-({2-[2-(2-{[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/23/2024
Entry Details
US Patent

TargetProtein cereblon(Human)
Monte Rosa Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 651649BDBM651649(US20240051936, Compound 55)
Affinity DataIC50: 900nMAssay Description:Compound activity was monitored in a fluorescence polarization (FP) homogeneous assay using 1-[5-({2-[2-(2-{[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/23/2024
Entry Details
US Patent

TargetProtein cereblon(Human)
Monte Rosa Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 651610BDBM651610(US20240051936, Compound 16)
Affinity DataIC50: 900nMAssay Description:Compound activity was monitored in a fluorescence polarization (FP) homogeneous assay using 1-[5-({2-[2-(2-{[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/23/2024
Entry Details
US Patent

TargetProtein cereblon(Human)
Monte Rosa Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 651643BDBM651643(US20240051936, Compound 49)
Affinity DataIC50: 900nMAssay Description:Compound activity was monitored in a fluorescence polarization (FP) homogeneous assay using 1-[5-({2-[2-(2-{[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/23/2024
Entry Details
US Patent

TargetProtein cereblon(Human)
Monte Rosa Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 651644BDBM651644(US20240051936, Compound 50)
Affinity DataIC50: 900nMAssay Description:Compound activity was monitored in a fluorescence polarization (FP) homogeneous assay using 1-[5-({2-[2-(2-{[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/23/2024
Entry Details
US Patent

TargetProtein cereblon(Human)
Monte Rosa Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 651645BDBM651645(US20240051936, Compound 51)
Affinity DataIC50: 900nMAssay Description:Compound activity was monitored in a fluorescence polarization (FP) homogeneous assay using 1-[5-({2-[2-(2-{[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/23/2024
Entry Details
US Patent

TargetProtein cereblon(Human)
Monte Rosa Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 651599BDBM651599(US20240051936, Compound 5)
Affinity DataIC50: 900nMAssay Description:Compound activity was monitored in a fluorescence polarization (FP) homogeneous assay using 1-[5-({2-[2-(2-{[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/23/2024
Entry Details
US Patent

TargetProtein cereblon(Human)
Monte Rosa Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 651603BDBM651603(US20240051936, Compound 9)
Affinity DataIC50: 1.55E+3nMAssay Description:Compound activity was monitored in a fluorescence polarization (FP) homogeneous assay using 1-[5-({2-[2-(2-{[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/23/2024
Entry Details
US Patent

TargetProtein cereblon(Human)
Monte Rosa Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 651635BDBM651635(US20240051936, Compound 41)
Affinity DataIC50: 1.55E+3nMAssay Description:Compound activity was monitored in a fluorescence polarization (FP) homogeneous assay using 1-[5-({2-[2-(2-{[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/23/2024
Entry Details
US Patent

TargetProtein cereblon(Human)
Monte Rosa Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 651620BDBM651620(US20240051936, Compound 26)
Affinity DataIC50: 1.55E+3nMAssay Description:Compound activity was monitored in a fluorescence polarization (FP) homogeneous assay using 1-[5-({2-[2-(2-{[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/23/2024
Entry Details
US Patent

TargetProtein cereblon(Human)
Monte Rosa Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 651621BDBM651621(US20240051936, Compound 27)
Affinity DataIC50: 1.55E+3nMAssay Description:Compound activity was monitored in a fluorescence polarization (FP) homogeneous assay using 1-[5-({2-[2-(2-{[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/23/2024
Entry Details
US Patent

TargetProtein cereblon(Human)
Monte Rosa Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 651630BDBM651630(US20240051936, Compound 36)
Affinity DataIC50: 1.55E+3nMAssay Description:Compound activity was monitored in a fluorescence polarization (FP) homogeneous assay using 1-[5-({2-[2-(2-{[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/23/2024
Entry Details
US Patent

TargetProtein cereblon(Human)
Monte Rosa Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 651615BDBM651615(US20240051936, Compound 21)
Affinity DataIC50: 1.55E+3nMAssay Description:Compound activity was monitored in a fluorescence polarization (FP) homogeneous assay using 1-[5-({2-[2-(2-{[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/23/2024
Entry Details
US Patent

TargetProtein cereblon(Human)
Monte Rosa Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 651601BDBM651601(US20240051936, Compound 7)
Affinity DataIC50: 1.55E+3nMAssay Description:Compound activity was monitored in a fluorescence polarization (FP) homogeneous assay using 1-[5-({2-[2-(2-{[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/23/2024
Entry Details
US Patent

TargetProtein cereblon(Human)
Monte Rosa Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 651633BDBM651633(US20240051936, Compound 39)
Affinity DataIC50: 1.55E+3nMAssay Description:Compound activity was monitored in a fluorescence polarization (FP) homogeneous assay using 1-[5-({2-[2-(2-{[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/23/2024
Entry Details
US Patent

TargetProtein cereblon(Human)
Monte Rosa Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 651642BDBM651642(US20240051936, Compound 48)
Affinity DataIC50: 1.55E+3nMAssay Description:Compound activity was monitored in a fluorescence polarization (FP) homogeneous assay using 1-[5-({2-[2-(2-{[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/23/2024
Entry Details
US Patent

TargetProtein cereblon(Human)
Monte Rosa Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 651612BDBM651612(US20240051936, Compound 18)
Affinity DataIC50: 1.55E+3nMAssay Description:Compound activity was monitored in a fluorescence polarization (FP) homogeneous assay using 1-[5-({2-[2-(2-{[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/23/2024
Entry Details
US Patent

TargetProtein cereblon(Human)
Monte Rosa Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 651606BDBM651606(US20240051936, Compound 12)
Affinity DataIC50: 1.90E+3nMAssay Description:Compound activity was monitored in a fluorescence polarization (FP) homogeneous assay using 1-[5-({2-[2-(2-{[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/23/2024
Entry Details
US Patent

TargetProtein cereblon(Human)
Monte Rosa Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 651607BDBM651607(US20240051936, Compound 13)
Affinity DataIC50: 1.90E+3nMAssay Description:Compound activity was monitored in a fluorescence polarization (FP) homogeneous assay using 1-[5-({2-[2-(2-{[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/23/2024
Entry Details
US Patent

TargetProtein cereblon(Human)
Monte Rosa Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 651608BDBM651608(US20240051936, Compound 14)
Affinity DataIC50: 1.90E+3nMAssay Description:Compound activity was monitored in a fluorescence polarization (FP) homogeneous assay using 1-[5-({2-[2-(2-{[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/23/2024
Entry Details
US Patent

TargetProtein cereblon(Human)
Monte Rosa Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 651609BDBM651609(US20240051936, Compound 15)
Affinity DataIC50: 1.90E+3nMAssay Description:Compound activity was monitored in a fluorescence polarization (FP) homogeneous assay using 1-[5-({2-[2-(2-{[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/23/2024
Entry Details
US Patent

TargetProtein cereblon(Human)
Monte Rosa Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 651602BDBM651602(US20240051936, Compound 8)
Affinity DataIC50: 1.90E+3nMAssay Description:Compound activity was monitored in a fluorescence polarization (FP) homogeneous assay using 1-[5-({2-[2-(2-{[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/23/2024
Entry Details
US Patent

TargetProtein cereblon(Human)
Monte Rosa Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 651604BDBM651604(US20240051936, Compound 10)
Affinity DataIC50: 1.90E+3nMAssay Description:Compound activity was monitored in a fluorescence polarization (FP) homogeneous assay using 1-[5-({2-[2-(2-{[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/23/2024
Entry Details
US Patent

TargetProtein cereblon(Human)
Monte Rosa Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 651616BDBM651616(US20240051936, Compound 22)
Affinity DataIC50: 1.90E+3nMAssay Description:Compound activity was monitored in a fluorescence polarization (FP) homogeneous assay using 1-[5-({2-[2-(2-{[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/23/2024
Entry Details
US Patent

TargetProtein cereblon(Human)
Monte Rosa Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 651655BDBM651655(US20240051936, Compound 61)
Affinity DataIC50: 1.90E+3nMAssay Description:Compound activity was monitored in a fluorescence polarization (FP) homogeneous assay using 1-[5-({2-[2-(2-{[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/23/2024
Entry Details
US Patent

TargetProtein cereblon(Human)
Monte Rosa Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 651657BDBM651657(US20240051936, Compound 70)
Affinity DataIC50: 1.90E+3nMAssay Description:Compound activity was monitored in a fluorescence polarization (FP) homogeneous assay using 1-[5-({2-[2-(2-{[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/23/2024
Entry Details
US Patent

TargetProtein cereblon(Human)
Monte Rosa Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 651598BDBM651598(US20240051936, Compound 4)
Affinity DataIC50: 1.90E+3nMAssay Description:Compound activity was monitored in a fluorescence polarization (FP) homogeneous assay using 1-[5-({2-[2-(2-{[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/23/2024
Entry Details
US Patent

Displayed 1 to 50 (of 66 total ) | Next | Last >>
Jump to: